Un recrutement en avance - ACHAT - OC 12,2€
Quantum Genomics a annoncé hier après marché que le recrutement des patients de sa phase IIa présentait 4 mois d’avance par rapport à son planning initial. QGC001 est actuellement développé dans le traitement de l’Hypertension Artérielle. Au vu de l’accélération du recrutement des patients (plus de 50% des patients recrutés et plus d’un tiers des patients ont complètement terminé l’étude), il est tout à fait envisageable d’obtenir des résultats cliniques dès la fin du T1 16. Avec une POS de 25% sur le composé, nous ne modifions pas à ce stade nos estimations et confirmons ainsi notre recommandation à ACHAT et notre objectif de cours de 12,2€.Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.